Share Name Share Symbol Market Type Share ISIN Share Description
Quantum Phar. LSE:QP. London Ordinary Share GB00BRTL8Q42 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -4.00p -5.52% 68.50p 67.00p 70.00p 73.00p 65.00p 73.00p 582,498 16:35:23
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 88.8 -10.9 -16.9 - 115.85

Quantum Phar. (QP.) Latest News (5)

More Quantum Phar. News
Quantum Phar. Takeover Rumours

Quantum Phar. (QP.) Share Charts

1 Year Quantum Phar. Chart

1 Year Quantum Phar. Chart

1 Month Quantum Phar. Chart

1 Month Quantum Phar. Chart

Intraday Quantum Phar. Chart

Intraday Quantum Phar. Chart

Quantum Phar. (QP.) Discussions and Chat

Quantum Phar. Forums and Chat

Date Time Title Posts
22/8/201715:19Quantum Pharma PLC - Charts included.578
12/7/201609:05Quantum Pharma PLC904

Add a New Thread

Quantum Phar. (QP.) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:53:0373.0010,0007,300.00O
15:14:4467.702,7351,851.60O
15:11:5769.06698482.06O
14:09:2268.005,0003,400.00AT
14:09:1769.5010,0006,950.00AT
View all Quantum Phar. trades in real-time

Quantum Phar. (QP.) Top Chat Posts

DateSubject
22/8/2017
09:20
Quantum Phar. Daily Update: Quantum Phar. is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker QP.. The last closing price for Quantum Phar. was 72.50p.
Quantum Phar. has a 4 week average price of 53p and a 12 week average price of 49p.
The 1 year high share price is 91p while the 1 year low share price is currently 33p.
There are currently 169,117,640 shares in issue and the average daily traded volume is 1,080,331 shares. The market capitalisation of Quantum Phar. is £115,845,583.40.
16/8/2017
18:52
duncan doughnut: Well I'm home tonight to see my CLIN are in talks to buy my QP. and both shares are up :-] That's a win/win for me. CLIN are trading on a much higher rating that QP. so they can pay a good price and it would still be earnings enhancing. CLIN are making their move now before the growth here really starts to show. I think the new board will hold out for a good price as they haven't even had time to stamp their mark and the company would be taken away from them just as they were going to get the credit. CLIN are 10 times the size of QP., easily in their scope to buy. Bid has to be in 3 fig share price I'd say, if it's to go through. Perhaps after the interims investors will get a better idea of the value here and appreciate what a bid price would need to be.
08/8/2017
12:40
rivaldo: New interview with the CEO: Http://www.chroniclelive.co.uk/business/business-news/quantum-pharma-fundamentally-successful-simplifying-13443064 Extracts: "Quantum Pharma 'fundamentally successful' in simplifying strategy, says chief executive" "Quantum Pharma’s new business model has been hailed as a “fundamental success” by chief executive Chris Rigg, three months after he closed the company’s struggling NuPharm division." "Mr Rigg said that Quantum’s effort to focus its business is now paying off. Speaking to The Journal Mr Rigg said: “The position that the business brought to float was the ability to convert unlicensed medicines to licensed. It then acquired NuPharm. “It was the business I closed, and it was a business that was failing. It was acquired for the right strategic intent but it was failing. “Part of what I have done is to focus and simplify the business. “When you license a product we bring it to market at a lower price than the unlicensed medicine. We can do that as we get a higher market share and manufacture it in bulk. “The aim is to drive into the future the benefits of the license programme to lower prices in the NHS.” Under the renewed strategy Quantum is focusing on its core business. This is largely the supply of unlicensed medications – known as specials – and the creation of licensed products through its Colonis arm. With its network of pharmacies across the UK, Quantum is a market leader in supplying adapted medicines to the market. This process can involve making liquid versions of pills or changing the flavour of medication. One of the key areas for growth for the firm is Colonis and its licensing division. Once a drug successfully attains a UK license the business involves becomes the only one able to distribute the medication to pharmacies. This gives its a major market advantage. As part of the new model Mr Rigg has appointed new management teams to oversee its divisions, including Colonis. “From a control perspective it allows you to focus,” said Rigg. “You can change and make people accountable.” Despite writing off £13.7m as a result of the NuPharm sale, Mr Rigg said investors reacted well to the renewed focus on its core business. The company’s share price reflected his optimism, and following the closure of NuPharm, Quantum’s share price soared from 43p to 60p over seven days. The price has since levelled off and at the time of writing sits at 55.25p."
26/6/2017
14:13
rivaldo: Just been tipped: Http://www.aol.co.uk/money/2017/06/26/these-growth-stocks-are-trading-at-major-discounts/ "In fact, here are two stocks which appear to be cheap based on their future prospects. But does that mean they are worth buying today? Impressive update Reporting on Monday was service-led niche pharmaceutical developer, Quantum Pharma(LSE: QP). The company announced the disposal of Total Medication Management Services, which is a homecare dispensary and delivery business which trades as Biodose Services. The disposal is another significant step in the transition of the business as it seeks to focus on its core Specials and Niche Pharmaceuticals divisions. The initial cash consideration on disposal will be £1.75m, with a maximum additional contingent consideration of £0.2m. The sale of the division improves Quantum Pharma's EBITDA (earnings before interest, tax, depreciation and amortisation) margin by eliminating low-margin turnover. In addition, the company's remaining divisions have traded ahead of expectations in the early months of the year. The company expects this to offset the majority of the disposed contribution from Biodose Services in the current year. Looking ahead, Quantum Pharma is expected to report a rise in its bottom line of 31% in the next financial year. Even after today's 3%+ rise in its share price, this leaves the business trading on a price-to-earnings growth (PEG) ratio of just 0.4. This suggests its capital growth potential is high, which means it may be worth buying for the long term."
21/2/2017
17:12
r ball: I'm always wary of roadshows. Why bother if you don't want to raise money. It's managements job to run the business not pander to existing investors or the share price.
20/10/2016
17:24
werewolfie: New boss for North East firm as it aims to raise £15million from markets 14:24, 20 OCT 2016 UPDATED 14:24, 20 OCT 2016 BY GRAEME WHITFIELD Chris Rigg has been acting CEO of firm Quantum since August but has now been appointed permanent chief executive Quantum Pharma Pharmaceutical firm Quantum has appointed a new chief executive and chairman and raised £15m from the markets as it seeks to recover from recent troubles. Chris Rigg, who has previously worked for Deloitte, Barclays and recruitment firm NRG in the North East, has been acting CEO since August and has now been confirmed in the top job. Quantum Pharma Plc issued a profit warning earlier this month and saw its share price plunge, but Mr Rigg has been backed by major shareholders in his strategy to simplify the hotly-tipped group and concentrate on its core specials business and niche pharmaceuticals pipeline. The firm has also appointed a new chairman, Ian Johnson, and two new non-executive directors - Christopher Mills and Dr John Brown – in a wideranging set of changes at the group’s board level. Quantum Pharma laboratories This morning the company had announced plans for an “accelerated bookbuild” that aimed to raise £15m to help reduce its debt. Just over an hour later, the company announced that the process had been successful. Shares in Quantum rose more than 25% after the announcements. Mr Rigg, who will remain as finance chief as well as CEO until a replacement is found, said: “I am delighted to be appointed as Quantum’s CEO and would like to thank the board and our major shareholders for their support. “Whilst the group has faced some challenges in the recent past, the focused and simplified strategy now in place has the potential to drive shareholder value and I look forward to working with Ian, Christopher, John and Quantum’s senior management team to deliver this.” Quantum warned earlier this month that its full-year results would be below forecasts, even though its six months to July 31 were strong, with revenues rising from £34.3m to £42.8m. The firm is also proposing to close a manufacturing operation in North Wales, a move affecting 66 employees. Mr Rigg replaces Andrew Scaife, who resigned in July. It has now been announced that chairman John Clarke and non-executive director Sheila Kelly have resigned from the company’s board.
04/10/2016
10:04
frankwhite: WereWolfie I was in the same boat as you and still sold out! That's how much confidence I have that this share price will go even lower than today's. Long term I do not see any growth with this company. I've switched what was left into OPTI which looks like a winner long term.
31/8/2016
13:51
rivaldo: Yep, steady as she goes. The H2 reliance is a drag, and a hindrance on H1 share price progression, but is well known. N+1 Singer have left forecasts unchanged and conclude that "The shares have begun to recover in recent weeks as a number of products have launched. We expect this trend to continue and for the shares to continue to re-rate on further delivery from the pipeline". They also say: "Another in line trading update confirms progress remains on track, both with trading in the core Specials division and delivery of new products from the Niche Pharmaceuticals pipeline now coming through as expected. We make no change to our forecasts and intend to review things more fully at the interims on 4th October, when we should have a clearer idea on how the commercialisation of those new products is progressing. We continue to see substantial potential upside in the shares on successful execution of the unlicensed to licensed strategy."
20/8/2016
10:04
werewolfie: I asked the same question on LSE website and someone responded with a very interesting post - QP's share price has a lot of ground to make up... But is making great progress due to the following:- (1) Appointment of new CFO Chris Rigg currently acting CEO (2) Appointment of a new CEO (details awaited) (3) Removal of Andrew Scaife (4) A validated pipeline of new products being approved and launched substantially more effectively than previous. (5) Uniqueness of Bio Dose / Bio Dose connect. (6) On track to meet target earnings and EBITDA for 16/17 (7) The appointment of Lisa Brigham as its corporate communications manager,This is real evidence that QP is serious about improving its Marketing and Wider Communications ability to improve both Sales, Margin and importantly Communications with shareholders / stakeholders... Including Institutional shareholders.. (8) The addition of the Slater Investments to the Major Shareholder List. There appears also to be a number of large trades going through the market over the past week... It might be Mr Scaife reducing his not insubstantial holding... But it appears at least to me either other Major shareholders are topping up ( an RNS will confirm this in the near future) or a predator is stake building.. There are a limited number of free Float shares and if institutions are topping up then we can expect further rises in the value of QP shares in the run up to interim results.. The appointment of the new CEO should add further impetus to the share price... Product launches should remain a secret until final approval and launch plans confirmed in order to stop competitors either copying or attempting to derail QP's launch plans ... Hence no sight of them on the Company website.. QP has previously quoted a total Pipeline of X products (audited externally) and an estimated overall value to the company... No doubt that this is being added to continuously. This is a unique company and with the changes detailed above and a set of unique products and services .. We have a real opportunity to retrace previous high's in its share price,
15/7/2016
23:00
rosejs2: As an update to my comment on the 5th April... (1) The should seriously be considering Nicola Massey as the new CEO (an In house appointee who has been in the company for best part of 9 months and has brought badly needed expertise in to her division and no doubt will have formed a real insight into how QP should go forward... (2) A new Chairman is needed... Whilst he has wielded the knife on Mr Scaife this was probably down to Instutional pressure and NOT his prowess as Chair.... I suspect after the new CEO is installed he will move on .. (2A) Likewise with the Non Executives...Either they are invisible or near useless.. not sure which... New ones needed with more business experience and more business savvy. (3) Scaife was a deal maker not a Pharma man and therefore not the man to take QP forward.. (4) Marketing at QP is in my opinion an amateurish operation and needs a complete overhaul... Without marketing excellence the release of new products and growth of existing products will not be achieved.. (5) Biodose should be licensed across the world for significant income streams whilst QP controls its roll out across the UK... What are QP waiting for?... Again ..poor marketing. (6) The company should consider buying Mr Scaife's shareholding and holding either as Treasury Shares for later placing with institutions once the price has risen (substantially) (7) With the CEO now destined to leave sooner rather than later... a predator may surface to pounce whilst the leadership of the company is under review... 5 Apr '16 If the Invisible Chairman can find the time to do a decent job at QP... Which I think is pretty doubtful.. He should address the Issue of the current CEO whose performance as recognised by the share price is Woeful... Nicola Massey should be given the role of CEO Immediately and be allowed to use her skill, judgement and experience to refocus QP into the Growth entity it was designed to be... Are the Institutions happy with QP... They will be when Scaife moves or is moved on to pastures new..
31/3/2016
16:02
rosejs2: Buffy on the 19th Jan Was aware of the following... Quantum Pharma said its directors report group adjusted EBITDA for the year to Jan. 31 is expected to be about GBP12.7m, versus market consensus of GBP13.4m. "Overall the Group has progressed significantly in FY 2016," it said in a statement. "However, the Niche Pharmaceutical division has experienced delays in its product pipeline. As a result of this, the Board now expects more moderate double digit revenue and EBITDA growth for FY 2017." This to my knowledge has NOT been downgraded further... What is becoming apparent is the unusual pattern in share trading..Small share trades including trades of 25, 27, 37 shares... Lots of AT trades of 5000.. I am no expert at all on interpreting what I might regard as share manipulation... all legal of course.. but I would not be surprised to find that somebody or some organisation are not building or manipulating the share price for their advantage.. including a possible takeover at a less than generous price to existing shareholders.. The Weakness in QP I believe is a number of its senior team.. Don't rate the Chairman.. The Invisible Man - who should be replaced.. Don't Rate QP's NOMAD zeus... Hopeless in supporting the share price or selling the QP growth story.. Don't rate the Investor relations Dept - Hopeless Don't rate the PR advisors to QP... Change them immediately Sorry about the rant.. but QP has a number of real opportunities to create shareholder value...But changes at the top and with its advisers are needed.. Perhaps we might even see a return to Private ownership for QP.. nothing should be ruled out..
Quantum Phar. share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20170822 20:21:12